CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

Ostrom, Quinn T.; Gittleman, Haley; Truitt, Gabrielle; Boscia, Alexander L.; Kruchko, Carol; Barnholtz‐Sloan, Jill S.

doi:10.1093/neuonc/noy131

Cited by 1,646 publications

(1,253 citation statements)

References 62 publications

Supporting

Mentioning

1,175

Contrasting

Unclassified

Order By: Relevance

“…Gliomas are the most common malignant brain tumors with high recurrence and lethality rates . According to the classification of the World Health Organization (WHO), brain gliomas are categorized into four grades (I‐IV) .…”

Section: Introductionmentioning

confidence: 99%

High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma

et al. 2019

View full text Add to dashboard Cite

Aims To evaluate the clinical significance of coatomer protein complex subunit beta 2 (COPB2) in patients with glioma using a bioinformatics analysis. Methods Oncomine, GEO, and The Cancer Genome Atlas databases were used to examine the COPB2 transcript levels in glioma tissues. Gene expression profiles with clinical information from low‐grade glioma and glioblastoma (GBM) projects were analyzed for associations between COPB2 expression and clinicopathologic characteristics. Kaplan‐Meier survival and Cox regression analyses were used for survival analysis. Gene set enrichment analysis (GSEA) was conducted to screen the pathways involved in COPB2 expression. Gene set variation analysis (GSVA) and correlograms were performed to verify the correlations between COPB2 and inflammatory responses. Canonical correlation analyses examined whether COPB2‐high patients have more infiltrating inflammatory and immune cells. Results COPB2 was highly expressed in gliomas and high COPB2 expression correlated with shorter overall survival time and several poor clinical prognostic variables. GSEA indicated that some immune‐related pathways and other signaling pathways in cancer were associated with the COPB2‐high phenotype. The GSVA and canonical correlation analysis demonstrated that COPB2 expression was closely linked to inflammatory and immune responses, and higher immune cell infiltration. Conclusions COPB2 may be a potential prognostic biomarker and an immunotherapeutic target for glioma.

show abstract

Section: Introductionmentioning

confidence: 99%

High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The cerebellum is the primary initiation site for MB and more than 80% of cases are diagnosed in children under the age of 15 years with the peak age between 6 and 8 years . The annual incidence of MB is approximately 5 cases per 1 million individuals . MB is heterogeneous with distinct histopathological and molecular subgroups and arise from the distinct neuronal stem or progenitor cell populations during early life …”

Section: Introductionmentioning

confidence: 99%

PELP1 signaling contributes to medulloblastoma progression by regulating the NF‐κB pathway

Luo

Pratap

et al. 2019

Molecular Carcinogenesis

View full text Add to dashboard Cite

Medulloblastoma (MB) is the most common and deadliest brain tumor in children. Proline‐, glutamic acid‐, and leucine‐rich protein 1 (PELP1) is a scaffolding protein and its oncogenic signaling is implicated in the progression of several cancers. However, the role of PELP1 in the progression of MB remains unknown. The objective of this study is to examine the role of PELP1 in the progression of MB. Immunohistochemical analysis of MB tissue microarrays revealed that PELP1 is overexpressed in the MB specimens compared to normal brain. Knockdown of PELP1 reduced cell proliferation, cell survival, and cell invasion of MB cell lines. The RNA‐sequencing analysis revealed that PELP1 knockdown significantly downregulated the pathways related to inflammation and extracellular matrix. Gene set enrichment analysis confirmed that the PELP1‐regulated genes were negatively correlated with nuclear factor‐κB (NF‐κB), extracellular matrix, and angiogenesis gene sets. Interestingly, PELP1 knockdown reduced the expression of NF‐κB target genes, NF‐κB reporter activity, and inhibited the nuclear translocation of p65. Importantly, the knockdown of PELP1 significantly reduced in vivo MB progression in orthotopic models and improved the overall mice survival. Collectively, these results suggest that PELP1 could be a novel target for therapeutic intervention in MB.

show abstract

“…Although meningiomas do not grow from brain tissue but arise from the meninges covering the brain, they are referred to as brain tumors and account for approximately 37% of all primary brain and central nervous system tumors . The far majority of meningiomas are benign tumors that can be treated well and have a favorable long‐term prognosis . Current standard of care consists of neurosurgical resection of the tumor, which most likely relieves initial neurological deficits that result from mass effects of the tumor .…”

Section: Introductionmentioning

confidence: 99%

Subjective cognitive functioning in patients with a meningioma: Its course and association with objective cognitive functioning and psychological symptoms

et al. 2019

View full text Add to dashboard Cite

Objective Although meningioma patients show deficits in objective cognitive functioning (OCF) measured with neuropsychological tests, subjective cognitive functioning (SCF) has received little attention. We investigate SCF from pre‐ to postsurgery and its associations with OCF, psychological, sociodemographic, and clinical characteristics. Methods SCF was measured using the Cognitive Failures Questionnaire (CFQ) 1 day before (T0) and 3 (T3) and 12 months (T12) after surgery. Patients' scores were compared with normative data and changes over time were assessed. The neuropsychological battery CNS Vital Signs and the Hospital Anxiety and Depression Scale were administered. Correlations of SCF with OCF, psychological, sociodemographic, and clinical characteristics were explored. Results Patients reported significantly better SCF as compared with controls at T0 (N = 54) and T3 (N = 242), but not at T12 (N = 50). A significant decrease in group level SCF was observed from T0 to T12 (n = 24, P < .001). SCF was associated with anxiety at all time points (rs = −0.543 to −0.352) and with depression at T3 and T12 (r = −0.338 and −0.574), but not with OCF, sociodemographic, or clinical characteristics (rs = −0.202 to 0.288). Conclusions Meningioma patients experienced better SCF as compared with controls before and 3 months after surgery, which might be the result of phenomena related to disease and recovery. As the findings suggest that cognitive symptoms might increase later on, future studies should further investigate the course of SCF in meningioma patients. In clinical practice, measurements of SCF should be combined with those of OCF and psychological distress in order to determine whether and which interventions are needed.

show abstract

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

Abstract: This report presents the following population-based measures: incidence rates, mortality rates, and relative survival rates (for more information on definitions of terms and measures used see: http://www.cbtrus.org/glossary/ glossary1.html).

Cited by 1,646 publications

References 62 publications

High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma

High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma

PELP1 signaling contributes to medulloblastoma progression by regulating the NF‐κB pathway

Subjective cognitive functioning in patients with a meningioma: Its course and association with objective cognitive functioning and psychological symptoms

Contact Info

Product

Resources

About